Design, synthesis, and mechanistic study of novel isoflavone derivatives as mitochondrial complex I inhibitors for non-small cell lung cancer treatment
Bioorganic Chemistry · 2026-09 · 179 · 110036
DOI: 10.1016/j.bioorg.2026.110036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-09. Verfasst von Jiawei Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Education Key Laboratory of Molecular and Cellular Biology; Hebei Anti-Tumor Molecular Target Technology Innovation Center; Hebei Researc…. Hauptthemen laut MEDLINE: Isoflavones, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Drug Design. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Department of Education of Hebei Province, Hebei Normal University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains the most prevalent and lethal form of lung cancer, highlighting an urgent need for novel therapeutic agents. Given its status as a critical hub for tumor bioenergetics, mitochondrial complex I has emerged as a promising therapeutic target. In this study, to optimize the efficacy of our previously identified mitochondrial complex I inhibitor DBI-2, we designed and synthesized 27 novel isoflavone derivatives. Among them, compound IV-16 exhibited the most potent antiproliferative activity against human NSCLC A549 cells (IC50 = 0.43 μM), demonstrating a 2.7-fold increase in potency compared to the lead compound DBI-2, while maintaining low cytotoxicity against normal cells. Mechanistically, compound IV-16 suppressed the cellular oxygen consumption rate, which could be reversed by the complex II substrate succinate, confirming its specific inhibition of mitochondrial complex I. This binding mode was further elucidated by molecular dynamics simulations, highlighting dominant interactions with key residues GLU204 and PHE86. Furthermore, compound IV-16 significantly inhibited cell migration and induced apoptosis in vitro. Notably, compound IV-16 triggered autophagy by activating the AMPK signaling pathway and subsequently inhibiting the downstream mTOR/S6 axis. In silico ADMET prediction further indicated that compound IV-16 possesses favorable pharmacokinetic profiles and low toxicity risks. Collectively, this study elucidates the structure-activity relationships of these novel isoflavone derivatives and identifies compound IV-16 as a promising mitochondrial complex I inhibitor with therapeutic potential for the treatment of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ministry of Education Key Laboratory of Molecular and Cellular Biology; Hebei Anti-Tumor Molecular Target Technology Innovation Center; Hebei Research Center of the Basic Discipline of Cell Biology; College of Life Scie…
- College of Chemistry and Materials Science, Hebei Normal University, Shijiazhuang 050024, China.
Förderung
- Department of Education of Hebei Province
- Hebei Normal University
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Meng, N., Li, R., Liu, M., Ma, Y., Liu, X., Chen, J., & Cheng, Y. (2026). Design, synthesis, and mechanistic study of novel isoflavone derivatives as mitochondrial complex I inhibitors for non-small cell lung cancer treatment. Bioorganic Chemistry, 179, 110036. https://doi.org/10.1016/j.bioorg.2026.110036
Vancouver
Liu J, Meng N, Li R, Liu M, Ma Y, Liu X, et al. Design, synthesis, and mechanistic study of novel isoflavone derivatives as mitochondrial complex I inhibitors for non-small cell lung cancer treatment. Bioorganic Chemistry. 2026;179:110036. doi:10.1016/j.bioorg.2026.110036
BibTeX
@article{Liu2026,
author = {Liu, Jiawei and Meng, Ni and Li, Rulan and Liu, Mengru and Ma, Yueshan and Liu, Xifu and Chen, Jing and Cheng, Yu},
title = {Design, synthesis, and mechanistic study of novel isoflavone derivatives as mitochondrial complex I inhibitors for non-small cell lung cancer treatment},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {179},
pages = {110036},
doi = {10.1016/j.bioorg.2026.110036}
}
EUVIMED